🚀 VC round data is live in beta, check it out!
Demant Valuation Multiples
Discover revenue and EBITDA valuation multiples for Demant and similar public comparables like Convatec Group, Imeik Technology Development, Bausch + Lomb, Abbott India and more.
Demant Overview
About Demant
Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
Founded
1904
HQ
Employees
26.7K
Website
Financials (LTM)
EV
$9B
Demant Financials
Demant reported last 12-month revenue of $4B and EBITDA of $874M.
In the same LTM period, Demant generated $3B in gross profit, $874M in EBITDA, and $276M in net income.
Revenue (LTM)
Demant P&L
In the most recent fiscal year, Demant reported revenue of $4B and EBITDA of $860M.
Demant expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $874M | XXX | $860M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $276M | XXX | $244M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | — | — | $3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Demant Stock Performance
Demant has current market cap of $6B, and enterprise value of $9B.
Market Cap Evolution
Demant's stock price is $30.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $6B | 0.9% | XXX | XXX | XXX | $1.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDemant Valuation Multiples
Demant trades at 2.6x EV/Revenue multiple, and 10.8x EV/EBITDA.
EV / Revenue (LTM)
Demant Financial Valuation Multiples
As of March 22, 2026, Demant has market cap of $6B and EV of $9B.
Equity research analysts estimate Demant's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Demant has a P/E ratio of 23.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 10.8x | XXX | 11.0x | XXX | XXX | XXX |
| EV/EBIT | 15.3x | XXX | 15.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | 3.5x | XXX | XXX | XXX |
| P/E | 23.3x | XXX | 26.3x | XXX | XXX | XXX |
| EV/FCF | 21.7x | XXX | 20.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Demant Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Demant Margins & Growth Rates
Demant's revenue in the last 12 month grew by 8%.
Demant's revenue per employee in the last FY averaged $0.1M.
Demant's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Demant's rule of X is 43% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Demant Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 48% | XXX | 46% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Demant Public Comps
See public comps and valuation multiples for other Medical Devices and Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Convatec Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Imeik Technology Development | XXX | XXX | XXX | XXX | XXX | XXX |
| Bausch + Lomb | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Snibe | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Demant M&A Activity
Demant acquired XXX companies to date.
Last acquisition by Demant was on XXXXXXXX, XXXXX. Demant acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Demant
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDemant Investment Activity
Demant invested in XXX companies to date.
Demant made its latest investment on XXXXXXXX, XXXXX. Demant invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Demant
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Demant
| When was Demant founded? | Demant was founded in 1904. |
| Where is Demant headquartered? | Demant is headquartered in Denmark. |
| How many employees does Demant have? | As of today, Demant has over 26K employees. |
| Who is the CEO of Demant? | Demant's CEO is Soren Nielsen. |
| Is Demant publicly listed? | Yes, Demant is a public company listed on Nasdaq Copenhagen. |
| What is the stock symbol of Demant? | Demant trades under DEMANT ticker. |
| When did Demant go public? | Demant went public in 1995. |
| Who are competitors of Demant? | Demant main competitors are Convatec Group, Imeik Technology Development, Bausch + Lomb, Abbott India. |
| What is the current market cap of Demant? | Demant's current market cap is $6B. |
| What is the current revenue of Demant? | Demant's last 12 months revenue is $4B. |
| What is the current revenue growth of Demant? | Demant revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Demant? | Current revenue multiple of Demant is 2.6x. |
| Is Demant profitable? | Yes, Demant is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Demant? | Demant's last 12 months EBITDA is $874M. |
| What is Demant's EBITDA margin? | Demant's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Demant? | Current EBITDA multiple of Demant is 10.8x. |
| What is the current FCF of Demant? | Demant's last 12 months FCF is $435M. |
| What is Demant's FCF margin? | Demant's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Demant? | Current FCF multiple of Demant is 21.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.